Remove Clinical Development Remove Laboratories Remove Pharmacokinetics
article thumbnail

Continuous Innovation with WorldwideEdge™ — A World of a Difference in Bioanalytic Operations

Conversations in Drug Development Trends

Jayaprakash Kotha, MBBS, PhD, ASCP (SH), Vice President, Bioanalytical Laboratory Satish Kumar, MBB, Head of Process Improvement Continuous Innovation is a Cornerstone of Bioanalysis Approximately 80% of drugs that begin the research process fail to reach approval. What is one contributing factor that sets the 20% that do apart from the rest?

article thumbnail

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

PPD

Expertise that accelerates your clinical development success The PPD clinical research business of Thermo Fisher Scientific has significant experience in customized Phase I-IV metabolic clinical trials. Were applying that expertise and commitment to every aspect of developing and running successful GLP-1 studies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Form and Formulation

Sygnature Discovery

Leveraging years of experience, we efficiently advance your compounds through preclinical studies and reduce risks as you move into clinical development. Our talented team of scientists can assist you in crafting robust pre-clinical development strategies.

article thumbnail

Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021

The Pharma Data

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinical development program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21. No Pharmacokinetic Interaction Between Novel NNRTI MK-8507 and Islatravir.

article thumbnail

The essential role of recombinant phage display antibody libraries

Drug Target Review

These assays may include pharmacokinetic (PK) assays, which provide information on the drug’s properties, and immunogenicity assays for the detection of anti-drug antibodies (ADA), which can lead to adverse events and reduced efficacy. 2018 Dec 5;11(1):178–90.

article thumbnail

Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet

The Pharma Data

Key secondary objectives include measures of safety, pharmacokinetics, and anti-tumor activity (i.e. Secondary endpoints include duration of response (DOR), overall survival (OS), safety, and pharmacokinetics (PK). Overall Response Rate (ORR) and Duration of Response, as determined by appropriate histology-specific response criteria).

article thumbnail

RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small.

The Pharma Data

Vice President, Clinical Development, Solid Tumors, Janssen Research & Development, LLC. “We entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib. **In 2018, Janssen Biotech, Inc. The most common Grade 3 or 4 laboratory abnormalities (?2%)